The forward P/E of 1.50x appears anomalous, likely reflecting a data artifact or extreme near-term earnings expectations, and should be treated with caution. The PEG of 0.42 implies the market is pricing in minimal growth, yet the underlying medical seat scarcity and recurring tuition model suggest a more durable earnings stream. Investors should monitor whether the discount narrows as regulatory clarity improves, but the current multiple may already compensate for policy uncertainty.

The sequential operating margin drop aligns with seasonal SG&A timing, but the 10-quarter range of 27.8% to 39.8% shows sensitivity to campus maturation and integration costs. Net margin of 20.3% in 2026Q2 remains healthy, though it understates cash generation due to acquisition-related amortization. The stable gross margin suggests pricing power persists, but any regulatory-driven seat expansion could pressure tuition premiums, warranting close monitoring.

ROE of 4.2% and ROA of 2.1% are similarly low, but these metrics are distorted by the $1.5B goodwill base and the early-stage maturation of new campuses. The underlying cash returns are stronger, as cumulative operating cash flow of $3.53B exceeded net income of $1.84B over ten quarters, per financial statements. Investors should adjust for intangible amortization and seat maturation to assess true economic returns, which likely exceed reported figures.

DSO has risen from 67 to 77 days over the last ten quarters, per financial statements, suggesting slower collections possibly tied to FIES receivables, which warrants monitoring for impairment risk. DPO has compressed from 140 to 33 days, reducing the negative CCC to near zero, which may reflect changing payment terms or acquisition integration. The asset turnover of 0.11x is low due to the capital-intensive campus model, but the negative CCC historically provided a cash flow buffer that is now narrowing.

The debt-to-equity ratio of 0.63 is moderate, but the high D/EBITDA reflects EBITDA that is depressed by acquisition amortization, making the leverage appear worse than cash flow suggests. Interest coverage of 2.39x is below the 3x comfort threshold, yet operating cash flow consistently exceeds net income, providing a cushion. The recent re-introduction of Mais Médicos could increase seat supply and pressure EBITDA, so investors should monitor whether coverage deteriorates further.

The quick ratio equals the current ratio at 2.20, reflecting minimal inventory dependence, which is typical for a service-based education model. The improvement from below 1.0 in mid-2025 suggests deliberate deleveraging or working capital management, but the seasonality of tuition collections creates swings. Under a severe stress scenario, the $1.0B cash buffer and negative CCC history provide resilience, though FIES receivable collection delays could strain liquidity if government payments lengthen.